MTOR and nonpapillary renal cell carcinoma: Targeted therapies, such as tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) protein inhibitors like everolimus, are the main adjuvant treatment strategies for ccRCC patients’ post-surgery [9, 10].